Louisiana is currently home to 891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Orleans, Baton Rouge, Shreveport and Metairie. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145
Recruiting
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b LTS (LTS16004) or 1 of the 4 Phase 3 tolebrutinib pivotal trials (GEMINI 1 \[EFC16033\], GEMINI 2 \[EFC16034\], HERCULES \[EFC16645\], or PERSEUS \[EFC16035\]). SUBSTUDY: ToleDYNAMIC substudy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: The NeuroMedical Center- Site Number : 8400057, Baton Rouge, Louisiana
Conditions: Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Register for Updates
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
NCT06224348
Recruiting
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe atopic dermatitis (AD) with a history of inadequate response of topical treatment, on background topical corticosteroid (TCS) and/or topical calcineurin inhibitor (TCI). The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/06/2025
Locations: BRCR Global Gretna- Site Number : 8401243, Gretna, Louisiana
Conditions: Dermatitis Atopic
Register for Updates
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
NCT06024746
Recruiting
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: CON-10030 Baton Rouge, LA Investigational Site, Baton Rouge, Louisiana
Conditions: Heart Failure
Register for Updates
Amnio-Maxx in Patients with Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone
NCT06572839
Recruiting
This randomized controlled study evaluates the adjuvant use of Amnio-Maxx in patients with diabetic foot ulcers
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Medcentris, Hammond, Louisiana
Conditions: Diabetic Foot Ulcer
Register for Updates
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This eve... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/05/2025
Locations: NeuroMedical Clinic of Central Louisiana- Site Number : 8401159, Alexandria, Louisiana
Conditions: Multiple Sclerosis
Register for Updates
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972
Recruiting
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
03/05/2025
Locations: Accurate Clinical Research, Lake Charles, Louisiana
Conditions: Systemic Lupus Erythematosus
Register for Updates
TeleHealth Model to Address Vaccine Hesitancy & Increase Vaccine Completion Among Communities in Southeastern Louisiana
NCT05676970
Recruiting
This study is a 24-30 month behavioral intervention study to assess the impact of enrolling individuals a clinical pharmacist run telehealth education focused on wellness and vaccination. Individuals will be randomized to either a wellness only model focusing on nutrition, diabetes and hypertension or a wellness model with a vaccination education component. All participants will complete individual and group based interventions. Individuals will be recruited from industries with high risk for CO... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/05/2025
Locations: Xavier University of Louisiana, New Orleans, Louisiana
Conditions: Vaccine Hesitancy
Register for Updates
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114
Recruiting
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
03/05/2025
Locations: Ochsner Clinic Foundation, Baton Rouge, Louisiana
Conditions: Systemic Lupus Erythematosus
Register for Updates
Myriad™ Augmented Soft Tissue Reconstruction Registry
NCT05243966
Recruiting
This is an observational study designed to evaluate the safety and clinical outcomes of Myriad™ in soft tissue reconstruction procedures. The study will enroll participants who are undergoing a surgical procedure, where the attending physician will use Myriad™ as part of the surgical intervention.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: University Medical Center, New Orleans, Louisiana
Conditions: Abdominal Wound Dehiscence, Necrotizing Soft Tissue Infection, Lower Extremity Wound, Pilonidal Sinus, Anal Fistula, Hidradenitis Suppurativa, Pressure Injury
Register for Updates
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640
Recruiting
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana
Conditions: Carcinoma, Non-Small-Cell Lung, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms, Colorectal Neoplasms
Register for Updates
Impact of the Wingate Test on Post-activation Potentiation
NCT06779409
Recruiting
The goal of this trial is to see if using a maximal effort, short cycling test is better at activating muscles to improve vertical jump height compared to a maximal effort back squat. The study looks to answer three questions: 1. will the Wingate bike test create a different change in counter movement jump height compared to a back squat? 2. What is the best recovery period after each test where the counter movement jump is the highest? 3. What person-specific factors predict success of the Win... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
03/04/2025
Locations: LSU Health Shreveport School of Allied Health Professions, Shreveport, Louisiana
Conditions: Performance Enhancement, Muscle Activation
Register for Updates
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236
Recruiting
This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemothe... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Trials365, LLC, Shreveport, Louisiana
Conditions: Platinum-resistant Ovarian Cancer
Register for Updates